Author: PX
Evaluating the value of supportive medical apps during the treatment for breast cancer
Young-Afat et al, 2014; Amsterdam EBCC9.
First place in the Digital Health Masterclass Challenge 2013
Px HealthCare won first place in the Digital Health Masterclass Challenge held by Janssen Healthcare Innovation and Johnson & Johnson Innovation.
NHS Innovation Accelerator
Anne joined the NHS Innovation Accelerator (NIA) from the Netherlands … Continue reading “NHS Innovation Accelerator”
Optimising oncology outcomes with a mobile app for breast cancer patients: A qualitative evaluation.
2016 NCRI Conference
Is there value in using patient recorded outcome measures to improve toxicity management patients receiving chemotherapy for breast cancer?
2017 Annual British Oncology Pharmacy Association Symposium
Px HealthCare Presents Comparative Regional Evaluation of OWise Breast Cancer Patient Support App
Px HealthCare, the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence study at the San Antonio Breast Cancer Symposium 2023.
OWise receives top prize in Scotland’s Cancer Innovation Challenge
OWise was one of the projects selected to win the finals and progress to phase two of the Cancer Innovation Challenge!
OWise wins top NESTA Healthier Lives Data Fund Prize
Px Healthcare won £60,000 in funding from the Scottish Government to keep developing their products and scale them across Scotland.
Evaluating a digital tool for supporting breast cancer patients: a randomized controlled trial protocol (ADAPT)
Lidington et al., 2020; BMC. OWise is being assessed by the randomised clinical trial ADAPT at the Royal Marsden NHS Foundation Trust. Find out more here:
Evaluating mobile applications for Breast Cancer in Germany: A systematic review
A systematic review that evaluated if breast cancer apps can support patients, whereby the OWise app received the highest score.